Cumberland Q4 Revenues Jump 31% to $13.7M as Talicia Drives Growth
Cumberland reported Q4 net revenues of $13.7 million, up 31% year-over-year, and narrowed its net loss to $1.41 million thanks to Talicia’s $3.3 million contribution. Fiscal 2025 revenues rose 18% to $44.5 million while operating cash flow climbed to $4.9 million.
1. Q4 Results and Product Contributions
In the fourth quarter, Cumberland’s net revenues increased 31% to $13.7 million with product-level contributions of $3.3 million each from Talicia and Sancuso, $3.1 million from Kristalose, $2.8 million from Vibativ and $0.9 million from Caldolor. Operating expenses rose to $15 million from $12 million, driving a net loss of $1.41 million versus $1.90 million a year earlier.
2. Full-Year Financial Performance and Cash Flow
For fiscal 2025, the company delivered $44.5 million in net revenues, up 18% and meeting its double-digit growth target. Adjusted earnings improved by $2.7 million to $1.7 million, operating cash flow climbed to $4.9 million, and the credit facility balance was reduced by over $10 million, leaving $11.4 million in cash.
3. Strategic Initiatives and Pipeline Progress
Cumberland forged a U.S. co-marketing agreement for Talicia and secured approvals for Vibativ in China and Saudi Arabia and injectable ibuprofen in Mexico. A permanent J-code for Caldolor was established and Phase II top-line results for ifetroban in Duchenne muscular dystrophy heart disease earned FDA Fast Track designation.